US Edition
U.S. Nears ‘AI-Powered Drugs’ While Korea Faces Data Privacy Hurdles
Summary by businesskorea.co.kr
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
U.S. Nears ‘AI-Powered Drugs’ While Korea Faces Data Privacy Hurdles
The logo of Recursion Pharmaceuticals (Captured from Recursion Pharmaceuticals' website) Recursion Pharmaceuticals, a U.S.-based AI drug discovery company, has advanced six AI-discovered drug candidates to Phase 2 clinical trials. Among them, REC-994 recently showed positive results in a Phase 2 trial for cerebral cavernous malformation (CCM), with a 50% reduction in brain lesions. If Recursion secures regulatory approval for REC-994 within thre…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
